One Sam's Club Recall Pulled Almost 150,000 Boxes Of Treats Off The Shelves
There are times when coming across a surprise element in food can be a pleasure. Consider the king cake, which often contains a hidden figurine representing the baby Jesus: It has been a staple of celebrations for the Feast of the Epiphany for centuries. But the king cake is just one of many crowd-pleasing foods that conceal another delicious ingredient, from arancini — a delicious solution for your leftover rice problem — and piñata cakes to the mysterious Thanksgiving meat tsunami that is the turducken. Aside from finding the figurine in the king cake, plastic in your food is rarely cause for celebration however — and that's the situation addressed by a massive Sam's Club recall.
In December 2022, the Canada-based company Sublime Desserts issued a recall for 148,000 units of its Member's Mark Holiday Macarons (sold exclusively at Sam's Club) because of potential contamination from plastic particles. Because the macarons were frozen, there was concern that consumers might keep them long after the initial purchase (the products did not expire until October to December 2023, according to the dates on the packaging). The Food and Drug Administration (FDA) labeled the action as a Class II recall, indicating that the contaminant might cause temporary or reversible health problems, but was unlikely to create serious or lasting health issues. No health problems related to the macarons were reported at the time of the recall.
Read more: Discontinued Costco Grocery Products We Probably Won't Get Back
Recalls are part of the business of running retail giants in the U.S. and abroad, and Sam's Club has not been immune to them. Over the past decade, Sam's Club food recalls have affected millions, for a variety of reasons. Salmonella was the culprit behind a recall of Jennie-O All Natural Turkey Burgers in 2011 and JIF peanut butter in 2022. The equally gruesome bacteria, listeria, led to the removal of various stone fruits in 2024 as well as 26 different kinds of muffins in 2021. Meanwhile, lack of accurate information caused a 2024 recall of Member's Mark Breaded Mozzarella Sticks. Rich Products, the producer of the breaded cheese sticks, failed to list soy and egg among the ingredients, both of which can cause serious health problems for those allergic to them.
Curiously, particles of plastic are at the heart of several Sam's Club recalls. What's meant by "plastic particles" is not the microplastics that are an unavoidable part of eating and drinking today, but larger pieces, such as those found in cans of Member's Mark Premium Natural Chunk Chicken Breast in Water in 2018 and frozen chicken nugget products from Tyson in 2014.
This list of recalls is in no way a criticism of Sam's Club. If anything, it underscores the retailer's commitment to keeping its customers safe and abiding by federal requirements to remove potentially hazardous food items.
For more food and drink goodness, join The Takeout's newsletter. Get taste tests, food & drink news, deals from your favorite chains, recipes, cooking tips, and more!
Read the original article on The Takeout.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
NeuroSigma Announces Notice of Allowance for Patent Protecting Monarch eTNS System in China
LOS ANGELES, June 10, 2025 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company commercializing the Monarch external Trigeminal Nerve Stimulation (eTNS) device for treating attention-deficit hyperactivity disorder (ADHD), today announced a notice of allowance in China for a patent protecting the Monarch eTNS System. The patent, titled Pulse Generator for Trigeminal Nerve Stimulation, protects certain embodiments of NeuroSigma's core eTNS technology, including its second-generation Monarch device. The patent was allowed by China's National Intellectual Property Administration on May 27, 2025. In 2022, NeuroSigma licensed rights to the Monarch eTNS System for treating ADHD in China to Ignis Therapeutics, a leader in the development of novel therapeutics for central nervous system (CNS) conditions. 'As NeuroSigma continues to grow and work with our partners at Ignis, China will be a critical market for the Monarch eTNS System,' said Colin Kealey, M.D., President and CEO of NeuroSigma. 'This patent protects our second-generation Monarch device in China and significantly strengthens the company's intellectual property position.' "NeuroSigma's Monarch eTNS System is a highly innovative and effective therapy for ADHD,' added Tom Paschall, Director of NeuroSigma and CEO of Checkmate Capital. 'China is one of the largest and most important markets in the world for new CNS therapies. With this patent award, the Monarch device will benefit from robust intellectual property protection, which, we believe, will facilitate commercialization in this key market.' About NeuroSigma NeuroSigma is a Los Angeles, California-based bioelectronic medical device company developing technologies to transform medical practice and patients' lives. The company's lead product is the Monarch eTNS System, which is the first non-drug treatment for pediatric ADHD cleared by the FDA. Pipeline indications for the Monarch eTNS System include neurodevelopmental disorders such as autism spectrum disorder (ASD), learning disabilities, and epilepsy. NeuroSigma has received Breakthrough Device Designation for the Monarch eTNS System from the FDA in drug-resistant epilepsy. For more information about NeuroSigma, please visit For more information on the Monarch eTNS System, please visit Contact:Colin Kealey, M.D., President of NeuroSigma at CKealey@


Business Wire
an hour ago
- Business Wire
Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of May 31, 2025
SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Median Technologies (Paris:ALMDT): About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit
Yahoo
an hour ago
- Yahoo
Phillips Medisize introduces medical connectors to enhance device integration
Molex company Phillips Medisize has introduced TheraVolt Medical Connectors to enhance integration, performance and functionality of the devices, addressing the needs of medical device engineers. The launch marks the company's entry into the medical connector market under its own brand. These connectors aim to meet the increasing demand, spurred by the quick adoption of pulsed field ablation (PFA) technology. They are said to offer improved functionality, handling both signals and high-voltage lines. TheraVolt Medical Connectors claim to have cross-platform compatibility, which simplifies device integration, extends the life of capital equipment, and minimises both customisation development time and expenses. This is particularly beneficial for the companies that develop PFA treatments for individuals with atrial fibrillation. The connectors offer several key features, including high pin count and voltage clearance, which facilitate the integration of additional functionalities into multi-therapy medical devices. They also provide flexibility of the design and customisation, with off-the-shelf availability and options for tailoring to specific application demands. Sterilisation compatibility is another key feature, as TheraVolt Medical Connectors are designed to withstand several autoclave cycles without compromising integrity and performance. Additionally, they are designed for safety and reliability, supporting compliance with IEC and IPC needs for dependable operation in medical applications. Phillips Medisize has announced that further medical connectors are currently being developed and are expected to be released in the next 18 to 24 months. Phillips Medisize medtech segment vice-president Pete Soupir said: 'With the launch of TheraVolt, the first of several Phillips Medisize–branded connectors, we are excited to bring deeper collaboration and innovation to complement our exceptional contract design and manufacturing services and proven Molex connectivity solutions to our medtech customers.' In 2023, Phillips Medisize partnered with GlucoModicum, a Finland-based medtech company, to work on a non-invasive, needle-free continuous glucose monitor. "Phillips Medisize introduces medical connectors to enhance device integration" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data